Get the Stockscreener App
4.94
3.35%
0.16
Recursion Pharmaceuticals Inc stock is traded at $4.94, with a volume of 19.82M.
It is up +3.35% in the last 24 hours and down -24.46% over the past month.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
See More
Previous Close:
$4.78
Open:
$4.8
24h Volume:
19.82M
Relative Volume:
0.75
Market Cap:
$2.11B
Revenue:
$64.60M
Net Income/Loss:
$-377.75M
P/E Ratio:
-3.1871
EPS:
-1.55
Net Cash Flow:
$-335.64M
1W Performance:
-14.38%
1M Performance:
-24.46%
6M Performance:
-46.77%
1Y Performance:
-32.79%
1-Day Range:
$4.78
$5.17
1-Week Range:
$4.72
$5.735
52-Week Range:
$3.79
$12.36
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Name
Recursion Pharmaceuticals Inc
Sector
Industry
Phone
(385) 269-0203
Address
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.94 | 2.40B | 64.60M | -377.75M | -335.64M | -1.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-22-23 | Initiated | Morgan Stanley | Equal-Weight |
| Mar-16-23 | Initiated | Needham | Buy |
| Sep-16-22 | Initiated | KeyBanc Capital Markets | Overweight |
| Apr-18-22 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-04-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-21-21 | Initiated | Berenberg | Buy |
| May-11-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Goldman | Neutral |
| May-11-21 | Initiated | JP Morgan | Neutral |
| May-11-21 | Initiated | KeyBanc Capital Markets | Overweight |
| May-11-21 | Initiated | SVB Leerink | Outperform |
View All
Recursion Pharmaceuticals Inc Stock (RXRX) Latest News
Recursion Pharmaceuticals Inc.’s Beta Climbs After Market VolatilityMarket Performance Report & Free Weekly Chart Analysis and Trade Guides - classian.co.kr
Why is RXRX Stock Declining? - StocksToTrade
Recursion Pharmaceuticals Inc. Shows Early Signs of Technical Strength2025 Earnings Surprises & Fast Exit/Entry Strategy Plans - mustnews.co.kr
Recursion Pharma to reduce workforce by 20% - MSN
Recursion Pharmaceuticals Shares Dip Amid Rising R&D Costs - TipRanks
Top Executive Sells Thousands of Shares in Major Pharmaceutical Firm! - TipRanks
Recursion pharma director Khan sells $202k in shares By Investing.com - Investing.com UK
Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data (NASDAQ:RXRX) - Seeking Alpha
Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX) - MSN
Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday? - MSN
Healthcare Stocks Receive Analyst Ratings: Cullinan Management, Recursion Pharmaceuticals, and Cochlear. - AInvest
RXRX Stock: Is It a Hidden Gem? - timothysykes.com
Recursion Pharmaceuticals (RXRX) Expands AI Drug Discovery Pipeline with New Clinical Candid - MSN
Why Recursion Pharmaceuticals Stock Faces Pressure - TipRanks
Recursion Pharmaceuticals (RXRX) Declines More Than Market: Some Information for Investors - MSN
Recursion Pharmaceuticals: Pioneering AI-Driven Drug Discovery to Redefine Precision Medicine and Deliver Outsized Returns - AInvest
Recursion Pharmaceuticals Expands AI Drug Discovery Pipeline with New Clinical Candidates - AInvest
Will Recursion Pharmaceuticals' (RXRX) Widening Losses Challenge Its Long-Term Innovation Story? - simplywall.st
Is Recursion Pharmaceuticals' AI-Driven Drug Discovery Model Worth the High-Risk Bet? - AInvest
Largest borrow rate increases among liquid names - MSN
Indicative Borrow Rate Increases Among Liquid Names: RXRX, POET, USAR, and More - AInvest
Here's Why Shares in Recursion Pharmaceuticals Surged Today - MSN
Recursion Pharmaceuticals (RXRX) Jumps 9.6% Ahead of Q2 Earnings - MSN
Support Zone Holds Steady for Recursion Pharmaceuticals Inc. After DipJuly 2025 Macro Moves & Trade Opportunity Analysis Reports - 선데이타임즈
Recursion Pharmaceuticals Insider Sold Shares Worth $3,263,964, According to a Recent SEC Filing - MarketScreener
Recursion Pharma CEO Gibson sells shares worth $3.26 million By Investing.com - Investing.com South Africa
Recursion Pharma CEO Gibson sells shares worth $3.26 million - Investing.com
Is Recursion On A Breakthrough Path? - timothysykes.com
Recursion Pharmaceuticals: Two Clinical Readouts In H2'25 (NASDAQ:RXRX) - Seeking Alpha
How Rising Losses and Revenue Growth at Recursion Pharmaceuticals (RXRX) Have Changed Its Investment Story - simplywall.st
From Novel Discovery to Precision Biomarkers: How Recursion is Using Data and AI to Deliver New Cancer Drugs - MarketScreener
Recursion outlines $100M partnership inflows target by end of 2026 as cash runway extends through Q4 2027 - MSN
3 Brilliant Growth Stocks to Buy Now and Hold for the Long Term - The Motley Fool
RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down - MSN
Recursion Bets Big On AI-Driven Drug Discovery, But Losses Mount - Finimize
Morgan Stanley Assumes Coverage of Recursion Pharmaceuticals (RXRX) Stock with an Equal Weight Rating - MSN
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript - MSN
Why Recursion Pharmaceuticals Stock Tanked on Tuesday - Mitrade
Bank of America Securities Remains a Hold on Recursion Pharmaceuticals (RXRX) - The Globe and Mail
Analysts Are Betting On Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) With A Big Upgrade This Week - 富途牛牛
Recursion Pharmaceuticals Reports Q2 Loss, Beats Revenue Estimates - AInvest
Broker Revenue Forecasts For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher - ca.finance.yahoo.com
Recursion Pharmaceuticals Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags - simplywall.st
Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
Recursion Pharmaceuticals shares fall 1.99% premarket after reporting a wider Q2 loss. - AInvest
Recursion Pharmaceuticals: Q2 Earnings Snapshot - Stamford Advocate
Recursion Pharmaceuticals Reports Q2 2025 Financial Results - TipRanks
Recursion (RXRX) Q2 Revenue Jumps 33% - AOL.com
Recursion Pharmaceuticals’ Earnings Call Highlights Progress and Challenges - TipRanks
Recursion Pharmaceuticals: Balancing AI Advancements with Financial Prudence Justifies Hold Rating - TipRanks
Recursion Pharmaceuticals and Biodexa: A High-Stakes Race in the FAP Market - AInvest
Recursion Pharmaceuticals Inc Stock (RXRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):